Reprinted from
WHO Chronicle, Vol. 18, No. 11, November 1964, pp. 433-444

International Non-Proprietary Names for Pharmaceutical Preparations

In accordance with paragraph 3 of the Procedure for the Selection of Recommended International Non-Proprietary Names for Pharmaceutical Preparations,[1] notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Non-Proprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in the *WHO Chronicle*.

The inclusion of a name in the lists of proposed international non-proprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.

PROPOSED INTERNATIONAL NON-PROPRIETARY NAMES (*Prop. I.N.N.*): LIST 14 [2]

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description*
acecarbromalum acecarbromal	1-acetyl-3-(α-bromo-α-ethylbutyryl)urea
acefyllinum piperazinum acefylline piperazine	piperazine 7-theophyllineacetate
aceperonum aceperone	4-[4-(acetamidomethyl)-4-phenylpiperidino]-4′-fluoro-butyrophenone
acidum asparticum aspartic acid	aminosuccinic acid
acidum etacrynicum etacrynic acid	[2,3-dichloro-4-(2-methylenebutyryl)phenoxy]acetic acid
acidum iobenzamicum iobenzamic acid	*N*-(3-amino-2,4,6-tri-iodobenzoyl)-*N*-phenyl-β-alanine
acidum iosefamicum iosefamic acid	5,5′-(sebacoyldiimino) bis[2,4,6-triiodo-*N*-methylisophthalamic acid]
acoxatrinum acoxatrine	(±)-*N*{[1-(1,4-benzodioxan-2-ylmethyl)-4-phenyl-4-piperidyl] methyl}acetamide
adenosini phosphas adenosine phosphate	5′-adenylic acid
adicillinum adicillin	(4-amino-4-carboxybutyl)penicillin

[1] See Annex, p. 441.

[2] Other lists of proposed international non-proprietary names can be found in *Chron. Wld Hlth Org.*, 1953, 7, 299; 1954, 8, 216, 313; 1956, 10, 28; 1957, 11, 231; 1958, 12, 102, *WHO Chronicle*, 1959, 13, 105, 152; 1960, 14, 168, 244; 1961, 15, 314; 1962, 16, 385; 1963, 17, 389.

Lists of recommended international non-proprietary names were published in *Chron. Wld Hlth Org.*, 1955, 9, 185; *WHO Chronicle*, 1959, 13, 106; 1962, 16, 101.

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description*
alcloxum alcloxa	tetrahydroxychloro[(2-hydroxy-5-oxo-2-imidazolin-4-yl)ureido] dialuminium
aldioxum aldioxa	dihydroxy[(2-hydroxy-5-oxo-2-imidazolin-4-yl)ureido]aluminium
allopurinolum allopurinol	1*H*-pyrazolo[3,4-*d*]pyrimidin-4-ol
almecillinum almecillin	[(allylthio)methyl] penicillin
amfetylinum amfetyline	7-[2-(α-methylphenethylamino)ethyl]theophylline
amicyclinum amicycline	9-amino-4-dimethylamino-1,2,3,4,4a,5,5a,6,11,11a,12,12a-dodeca-hydro-10,12a-dihydroxy-1,3,11,12-tetraoxonaphthacene-2-carboxamide
aminorexum aminorex	2-amino-5-phenyl-2-oxazoline
amiperonum amiperone	4-(*p*-chlorophenyl)-1-[3-(*p*-fluorobenzoyl)propyl]-*N*,*N*-dimethylisonipecotamide
anisopirolum anisopirol	(±)-α-(*p*-fluorophenyl)-4-(*o*-methoxyphenyl)-1-piperazinebutanol
argininum arginine	L(+)-arginine
azidamfenicolum azidamfenicol	D(—)-*threo*-2-azido-N-[β-hydroxy-α-(hydroxymethyl)-*p*-nitrophenethyl] acetamide
becantonum becantone	1-/{ethyl(2-hydroxy-2-methylpropyl)amino]-ethyl}amino/-4-methylthioxanthen-9-one
benperidolum benperidol	1-{1-[4-(*p*-fluorophenyl)-4-oxobutyl]piperidin-4-yl}-2-benzimidazolinone
benzetimidum benzetimide	2-(1-benzyl-4-piperidyl)-2-phenylglutarimide
bietaserpinum bietaserpine	methyl 1a,2β,3a,4aα,5,7,8,13,13bβ,14,14aα-dodecahydro-1-(2-diethyl-aminoethyl)-2,11-dimethoxy-3β-(3,4,5-trimethoxybenzoyloxy)-benz[g] indole-[2,3-a]quinolizine-1β-carboxylate *or* 1-(2-diethylaminoethyl)reserpine
bluensomycinum bluensomycin	an antibiotic substance obtained from cultures of *Streptomyces bluensis*, or the same substance produced by any other means
bronopolum bronopol	2-bromo-2-nitro-1,3-propanediol
butinolinum butinoline	1,1-diphenyl-4-pyrrolidino-1′-yl but-2-yn-1-ol
butoxylatum butoxylate	butyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate
buzepidi metiodidum buzepide metiodide	1-(3-carbamoyl-3,3-diphenypropyl) perhydro-1-methylazepinium iodide
cafedrinum cafedrine	7-[2-(2-hydroxy-1-methylphenethylamino)ethyl]theophylline
capuridum capuride	*N*-(2-ethyl-3-methylvaleryl)urea

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description*
carbocromenum carbocromen	ethyl 3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2*H*-1-benzopyran-7-yloxyacetate
carbubarbum carbubarb	5-butyl-5-(2-carbamoyloxyethyl)barbituric acid carbamate ester
cefalotinum cefalotin	3-(acetoxymethyl)-8-oxo-7-[2-(2-thienyl)-acetamido]-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylic acid
cepalonium cepalonium	3-(4-carbamoylpyridylmethyl)-8-oxo-7-[α-(thien-2-yl)acetamido]-5-thia-1-azabicyclo[4-2,0]oct-2-ene-2-carboxylic acid
cepaloramum cepaloram	3-(acetoxymethyl)-8-oxo-7-(phenylacetamido)-5-thia-1-azabicyclo [4.2.0]oct-2-ene-2-carboxylic acid
cetofenicolum cetofenicol	*D-threo*-2,2-dichloro-*N*-[*p*-[acetyl-β-hydroxy-α-(hydroxymethyl)phenethyl]]acetamide
clibucainum clibucaine	2,'4'-dichloro-β-piperidinobutyranilide
clofenoxydum clofenoxyde	α-(4-chlorophenoxy)-N-(2-diethylaminoethyl) acetamide
clofexamidum clofexamide	2-(*p*-chlorophenoxy)-*N*-[2-(diethylamino)ethyl] acetamide
clomethiazolum clomethiazole	5-(2-chloroethyl)-4-methylthiazole
clominorexum clominorex	2-amino-5-(*p*-chlorophenyl)-2-oxazoline
clorindanolum clorindanol	7-chloro-4-indanol
clorprenalinum clorprenaline	1-0-chlorophenyl-2-isopropylaminoethanol
cotininum cotinine	(−)-1-methyl-5-(3-pyridyl)-2-oxo-pyrrolidin compound (2:1) with fumaric acid
cyclazocinum cyclazocine	3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-6,11-dimethyl-2,6-methano-3-benzazocin-8-ol
cycliraminum cycliramine	4-(*p*-chloro-α-2-pyridyl benzylidene)-1-methylpiperidine
cytarabinum cytarabine	4-amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
dalanatum insulinum dalanated insulin	an insulin derivative prepared by the removal of the C-terminal alamine from the B chain of insulin
dantronum dantron	1,8-dihydroxyanthraquinone
deferoxaminum deferoxamine	30-amino-3,14,25-trihydroxy-3,9,14,20,25 pentaazatriacontane-2, 10,13,21,24-pentaone
demecyclinum demecycline	4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide
deslanosidum deslanoside	deacetyllanatoside C
dibenzepinum dibenzepin	10-[2-(dimethylamino)ethyl]-5,10-dihydro-5-methyl-11H-dibenzo[b,e] [1,4]diazepin-11-one

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description*
dibromsalanum dibromsalan	3-bromo-6-hydroxybenz-*p*-bromanilide
dimantinum dimantine	*N*,*N*,dimenthyl-*N*-octadecylamine
dimecolonii iodidum dimecolonium iodide	ester of 2-carboxy-1,1,6-trimethylpiperidinium iodide with (2-hydroxyethyl) trimethylammonium iodide
dimelazinum dimelazine	10-[(1,3-dimethyl-3-pyrrolidinyl)methyl]phenothiazine
dimevamidum dimevamide	4-(dimethylamino)-2,2-diphenylvaleramide
domoxinum domoxin	1-(1,4-benzodioxan-2-ylmethyl)-1-benzylhydrazine
droperidolum droperidol	1-{1-[4-(*p*-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridyl}-2-benzimidazolinone
estomycinum estomycine	an antibiotic substance obtained from cultures of *Streptomyces chrestomyceticus*, or the same substance produced by any other means
estrioli succinas estriol succinate	estra-1,3,5(10)-triene-3,16α,17β-triol 16,17-bis(hydrogen succinate)
etafedrinum etafedrine	2-ethylmethylamino-1-phenylpropan-1-ol
ethiazidum ethiazide	6-chloro-3-ethyl-3,4-dihydro-2*H*-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
etofyllinum etofylline	7-(2-hydroxyethyl)theophylline
etoglucidum etoglucid	1,2:15,16-diepoxy-4,7,10,13-tetraoxahexadecane
etosalamidum etosalamide	*o*-(2-ethoxyethoxy)benzamide
etozolinum etozolin	ethyl 3-methyl-4-oxo-5-piperidino-thiazolidinylidene-2-acetate
fenfluraminum fenfluramine	3-trifluoromethyl)-*N*-ethyl-α-methylphenethylamine
fenmetramidum fenmetramide	5-methyl-3-oxo-6-phenyl-3-morpholin
fenozolonum fenozolone	2-ethylamino-4-oxo-5-phenyl-2-oxazolin
fentalynum fentanyl	1-phenethyl-4-N-propionylanilinopiperidine
flucarbrilum flucarbril	1-methyl-6-2-oxo-trifluoromethylquinolin
fluminorexum fluminorex	2-amino-5-(α,α,α-trifluoro-*p*-tolyl)-2-oxazoline
flupentixolum flupentixol	2-trifluoromethyl-9-(3-[4-(2-hydroxyethyl) piperazin-1-yl]propylidene) thiaxanthen
formetorexum formetorex	*N*-(α-methylphenethyl)formamide

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description*
furosemidum furosemide	4-chloro-*N*-(2-furylmethyl)-5-sulfamoylanthranilic acid
furterenum furterene	2,4,7-triamino-6-(2-furyl)pteridine
gefarnatum gefarnate	*trans*-3,7-dimethyl-2,6-octadienyl 5,9,13-trimethyl-4,8,12-tetradecatrienoate
gentamycinum gentamycin	an antibiotic substance obtained from cultures of *Micromonospora purpurea*, or the same substance produced by any other means
glyoctamidum glyoctamide	1-cyclooctyl-3(*p*-tolylsulfonyl)urea
heptabarbum heptabarb	5-(1-cyclohepten-1-yl)-5-ethylbarbituric acid
heteronii bromidum heteronium bromide	3-hydroxy-1,1-dimethyl pyrrolidinium bromide, α-phenyl-2-thiopheneglycolate
hydracarbazinum hydracarbazine	6-hydrazino-3-pyridazinecarboxamide
hydrobentizidum hydrobentizide	3-[(benzylthio)methyl]-6-chloro-3,4-dihydro-2*H*-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
ibufenacum ibufenac	*p*-isobutylphenylacetic acid
iopydolum iopydol	1-(2,3-dihydroxypropyl)-3,5-diiodo-4(1*H*)-pyridone
iopydonum iopydone	3,5-diiodo-4(1*H*)-pyridone
kalii glucaldras potassium glucaldrate	potassium dihydroxy(gluconato)diaquoaluminate
lauromacrogolum 400 lauromacrogol 400	mixture of monolauryl ethers of polyoxyethylene glycols having a statistical average of 8 ethylene oxide groups per molecule
litracenum litracen	9-(3-methylaminopropylidene)-10,10-dimethyl-9,10-dihydroanthracene
lymecyclinum lymecycline	(+)-*N*-(5-amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide *or* N^2-{[(+)-5-amino-5-carboxypentylamino]methyl}tetracycline
maletamerum maletamer	maleic anhydride ethylene polymer
mebeverinum mebeverine	4-[ethyl(*p*-methoxy-α-methylphenethyl)amino]butyl 3,4-dimethoxybenzoate
meclocyclinum meclocycline	7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methylene-1,11-dioxonaphthacene-2-carboxamide
mefexamidum mefexamide	*N*-[2-(diethylamino)ethyl]-2(*p*-methoxyphenoxy) acetamide
meletimidum meletimide	(±)-2[1-(*p*-methylbenzyl)-4-piperidyl]-2-phenylglutarimide
melitracenum melitracen	9-(3-dimethylaminopropylidene)-10,10-dimethyl-9,10-dihydroanthracene

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description*
meprotixolum meprotixol	9-[3-(dimethylamino)propyl]-2-methoxy-thioxanthene-9-ol
mequinolum mequinol	4-methoxyphenol
metamfepramonum metamfepramone	2-(dimethylamino)propiophenone
metisazonum metisazone	1-methylindole-2,3-dione 3-(thiosemicarbazone)
metixenum metixene	1-methyl-3-[(thioxanthen-9-yl)methyl]piperidine
metoclopramidum metoclopramide	4-amino-5-chloro-*N*-[2-(diethylamino)ethyl]-2-methoxybenzamide
mimbanum mimbane	1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-13-methylbenz[g]-indolo [2,3a]quinolizine *or* 1-methylyohimbane
minocyclinum minocycline	4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-7-methylamino-1,11-dioxo-2-naphthacene carboxamide
moperonum moperone	4′-fluoro-4-(4-hydroxy-4-*p*-tolylpiperidino)butyrophenone
moxisylytum moxisylyte	[2-(4-acetoxy-2-isopropyl-5-methylphenoxy)ethyl]dimethylamine
natrii apolas sodium apolate	sodium ethenesulfonate polymer
natrii gualenas sodium gualenate	sodium 5-isopropyl-3,8-dimethyl-1-azulene sulfonate
nicofuranosum nicofuranose	D-fructofuranose 1,3,4,6-tetranicotinate
nifuroxazidum nifuroxazide	*p*-hydroxybenzoic acid 5-nitrofurfurylidene hydrazide
nifurthiazolum nifurthiazole	2-(2-formylhydrazino)-4-(5-nitro-2-furyl) thiazole
nitrocyclinum nitrocycline	4 β-dimethylamino-1,2,3,4,4a,5,5a,6,11,11a,12,12aα-dodecahydro-10, 12aα-dihydroxy-7-nitro-1,3,11,12-tetraoxo-2-naphthacenecarboxamide
norgesteronum norgesterone	17α-vinyl-5(10)-estrene-17β-ol-3-one
norpipanonum norpipanone	4,4-diphenyl-6-piperidino-3-hexanone
octacainum octacaine	3-diethylaminobutyranilide
orciprenalinum orciprenaline	3,5-dihydroxy-α-[(isopropylamino)methyl]benzyl alcohol
oxaboloni cypionas oxabolone cypionate	17β(3-cyclopentylpropionyloxy)-4-hydroxyestr-4-en-3-one
oxolaminum oxolamine	5-[2-(diethylamino)ethyl]-3-phenyl-1,2,4-oxadiazole
panthenolum panthenol	(±)-2,4-dihydroxy-*N*-(3-hydroxypropyl)-3,3-dimethylbutyramide

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description*
parapenzolati bromidum parapenzolate bromide	4-benziloyloxy-1,1-dimethylpiperidinium bromide
penmesterolum penmesterol	3-(cyclopentyloxy)-17-methyl-androsta-3,5-dien-17β-ol
pentagestroni acetas pentagestrone acetate	3-(cyclopentyloxy)-17-hydroxypregna-3,5-dien-20-one acetate
pentazocinum pentazocine	3-(3-methyl-2-butenyl)-1,2,3,4,5,6-hexahydro-8-hydroxy-6,11-dimethyl-2,6-methano-3-benzazocine
penthrichloralum penthrichloral	5,5-di(hydroxymethyl)-2-trichloromethyl-1,3-dioxan
pimethixenum pimethixene	1-methyl-4-(thioxanthen-9-ylidene)piperidine
polyetadenum polyetadene	1,2:3,4-diepoxybutane ethylenimine polymer
prazepamum prazepam	7-chloro-1-(cyclopropylmethyl)-1,3-dihydro-5-phenyl-2*H*-1,4-benzodiazepin-2-one
prilocainum prilocaine	2-methyl-α-propylamino-propionanilid
procymatum procymate	1-cyclohexylpropyl carbamate
prolonii iodidum prolonium iodide	(2-hydroxytrimethylene)bis[trimethylammonium iodide]
pronetalolum pronetalol	2-isopropylamino-1-(napth-2-yl)ethanol
propanididum propanidid	propyl{4-[(diethylcarbamoyl)methoxy]-3 methoxyphenyl}acetate
propiolactonum propiolactone	β-propiolactone
protheobrominum protheobromine	1-(2-hydroxypropyl)theobromine
protriptylinum protriptyline	*N*-3-(5*H*-dibenzo[*a*,*d*]cyclohepten-5-yl)propyl-*N*-methylamine
prozapinum prozapine	1-(3,3-diphenylpropyl)hexamethyleneimine
pyridofyllinum pyridofylline	5-hydroxy-3,4-di(hydroxymethyl)-6-methylpyridyl-2-(theophylline) ethoxysulfate
pyrinolinum pyrinoline	α,α-di-2-pyridyl-α-[β-di(2-pyridyl)methylenecyclopenta-1,4-dien-1-ylmethanol
pyrovaleronum pyrovalerone	4'-methyl-2-(1-pyrrolidinyl)valerophenone
quinacillinum quinacillin	6-(3-carboxy-2-quinoxalinecarboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
quinbolonum quinbolone	17β-(cyclopent-1-enyloxy)-androsta-1,4-dien-3-one
quindonii bromidum quindonium bromide	2,3,3a,5,6,11,12,12a-octahydro-8-hydroxy-1*H*-benzo[*a*]-cyclopenta[*f*] quinolizinium bromide

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description*
quinestrolum quinestrol	3-cyclopentyloxy-17α-ethynylestra-1,3,5(10)-trien-17β-ol
rolicyprinum rolicyprine	(+)-5-oxo-*N*-(*trans*-2-phenylcyclopropyl)-L-2-pyrrolidinecarboxamide
rutamycinum rutamycin	an antibiotic substance obtained from cultures of *Streptomyces rutgersensis*, or the same substance produced by any other means
simtrazenum simtrazene	1,4-dimethyl-1,4-diphenyl tetrazene
spiramidum spiramide	8-[3-(4-fluorophenoxy)propyl]-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one
spiroxasonum spiroxasone	α-acetylthio-4′,5′-dihydrospiro[androst-4-ene-17,2′(3′*H*)-furan]-3-one acetate
spiroxatrinum spiroxatrine	8-(1,4-benzodioxan-2-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4,5] decane-4-one
streptonigrinum streptonigrin	5-amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpicolinic acid
sulazepamum sulazepam	7-chloro-1,3-dihydro-1-methyl-5-phenyl-2*H*-1,4-benzodiazepine-2-thione
sulfamethoxazolum sulfamethoxazole	5-methyl-3-sulfanilamido-isoxazole
sulfametinum sulfametin	N^1-(5-methoxy-2-pyrimidinyl)sulfanilamide
sulfaperinum sulfaperin	N^1-(5-methyl-2-pyrimidinyl)sulfanilamide
terizidonum terizidone	4,4′-[*p*-phenylenebis(methyleneamino]di-(isoxazolidin-3-one)
theodrenalinum theodrenaline	7-{2-[2-(3,4-dihydroxyphenyl)2-hydroxyethylamino]-ethyl}-theophylline
theophyllinum ephedrinum theophylline ephedrine	theophylline-(-)-ephedrine compound
tigloidinum tigloidine	tiglyl*pseudo*tropine
tiocarlidum tiocarlide	4,4′-bis(isopentyloxy)thiocarbanilide
tiomesteronum tiomesterone	1α,7α-diacetylthio 17β-hydroxy-17-methylandrost-4-en-3-one
tocofersolanum tocofersolan	mono[2,5,7,8-tetramethyl-2-(4,8,12-trimethyl tridecyl)-6-chromanyl] succinate, polyoxyethylene ether
tolnaftatum tolnaftate	2-naphthyl *N*-methyl-*N*-(3-tolyl)thionocarbamate
tonzonii bromidum tonzonium bromide	hexadecyl{2-[p-methoxybenzyl)-2-pyrimidinylamino]-ethyl}dimethyl ammonium bromide
trethinii tosylas trethinium tosylate	2-ethyl-1,2,3,4-tetrahydro-2-methylisoquinolinium *p*-toluenesulfonate
triaziquonum triaziquone	tris-(1-azaridinyl)-*p*-benzoquinone

Proposed International Non-Proprietary Name (Latin, English)	*Chemical Name or Description*
tribromsalanum tribromsalan	3,5-dibromo-6-hydroxybenz-*p*-bromanilide
triclofenolum piperazinum triclofenol piperazine	piperazine di(2,4,5-trichlorophenoxide)
trimetazidinum trimetazidine	1-(2,3,4-trimethoxybenzyl)piperazine
tritoqualinum tritoqualine	7-amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)phthalide
tybamatum tybamate	2-methyl-2-propyltrimethylene butylcarbamate carbamate
xantofyli palmitas xantofyl palmitate	β-carotene-4,4′-diol dipalmitate

Annex

PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS *

The following procedure shall be followed by the World Health Organization in the selection of recommended international non-proprietary names for pharmaceutical preparations, in accordance with the World Health Assembly resolution WHA3.11:

1. Proposals for recommended international non-proprietary names shall be submitted to the World Health Organization on the form provided therefor.

2. Such proposals shall be submitted by the Director-General of the World Health Organization to the members of the Expert Advisory Panel on the International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, for consideration in accordance with the " General principles for guidance in devising International Non-proprietary Names ", appended to this procedure. The name used by the person discovering or first developing and marketing a pharmaceutical preparation shall be accepted, unless there are compelling reasons to the contrary.

3. Subsequent to the examination provided for in article 2, the Director-General of the World Health Organization shall give notice that a proposed international non-proprietary name is being considered.

A. Such notice shall be given by publication in the *WHO Chronicle* and by letter to Member States and to national pharmacopoeia commissions or other bodies designated by Member States.

(i) Notice may also be sent to specific persons known to be concerned with a name under consideration.

B. Such notice shall:

(i) set forth the name under consideration;

(ii) identify the person who submitted a proposal for naming the substance, if so requested by such person;

(iii) identify the substance for which a name is being considered;

(iv) set forth the time within which comments and objections will be received and the person and place to whom they should be directed;

(v) state the authority under which the World Health Organization is acting and refer to these rules of procedure.

C. In forwarding the notice, the Director-General of the World Health Organization shall request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the proposed name during the period it is under consideration by the World Health Organization.

* Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.*, 1955, 60, 3).

4. Comments on the proposed name may be forwarded by any person to the World Health Organization within four months of the date of publication, under article 3, of the name in the *WHO Chronicle*.

5. A formal objection to a proposed name may be filed by any interested person within four months of the date of publication, under article 3, of the name in the *WHO Chronicle*.

A. Such objection shall:

(i) identify the person objecting;

(ii) state his interest in the name;

(iii) set forth the reasons for his objection to the name proposed.

6. Where there is a formal objection under article 5, the World Health Organization may either reconsider the proposed name or use its good offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by the World Health Organization of a substitute name or names, a name shall not be selected by the World Health Organization as a recommended international non-proprietary name while there exists a formal objection thereto filed under article 5 which has not been withdrawn.

7. Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the Director-General of the World Health Organization shall give notice in accordance with subsection A of article 3 that the name has been selected by the World Health Organization as a recommended international non-proprietary name.

8. In forwarding a recommended international non-proprietary name to Member States under article 7, the Director-General of the World Health Organization shall:

A. request that it be recognized as the non-proprietary name for the substance; and

B. request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name, including prohibiting registration of the name as a trade-mark or trade-name.

General Principles for Guidance in Devising International Non-Proprietary Names for Pharmaceutical Preparations *

1. Names should be distinctive in sound and spelling. They should not be inconveniently long and should not be liable to confusion with names already in common use.

2. The name for a substance belonging to a group of pharmacologically related substances should show this relationship. The name should be free from any anatomical, physiological, pathological or therapeutic suggestion.

The above primary principles are to be implemented by utilization of the following secondary principles.

3. In devising the name of the first substance in a new pharmacological group (the parent substance), consideration should be given to the possibility of devising suitable names for related substances belonging to the new group.

4. Syllables such as " methylhydro " and " chlor " should preferably be abbreviated (to " medro " and " clo ", etc.).

5. Names for substances which are used as salts should in general apply to the active base (or the active acid). Names for different salts or esters of the same active substance should differ only in respect of the name of the inactive acid (or the inactive base). Exceptions may have to be made for those cases in which pharmacological activity may reside in both parts of the salt or ester.

For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a quaternary substance and not in the amine-salt style.

6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.

7. To facilitate translation and pronunciation " f " should preferably be used instead of " ph ", " t " instead of " th ", and " e " instead of " ae " or " oe ".

* As revised in November 1963 by the Sub-Committee on Non-Proprietary Names of the Expert Committee on Specifications for Pharmaceutical Preparations.

8. Provided that the names suggested are in accordance with these principles, names proposed by the persons discovering or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should receive preferential consideration.

9. Group relationship in names (see item 2) should preferably be shown by using common syllables in the following list. Where a syllable or a group of syllables is shown without any hyphens it may be used anywhere in the name. The syllable, or group of syllables, should, if possible, be used only for such substances.

Subsidiary group relationships should be shown by devising names which show similarities to and are analogous with a previously named substance, the parent substance.

At the end of the list are general chemical syllables. Should they come into conflict with other suggested syllables, the suffix conveying the best information should be used.

Latin	*English*	*French*	
-andr-	-andr-	-andr-	steroids, androgenic
or -stan-	or -stan-	or -stan-	
or -ster-	or -ster-	or -ster-	
-arolum	-arol	-arol	anticoagulants
-barbum-	-barb	-barbe	barbituric acids
bol	bol	bol	anabolic steroids
-cainum	-caine	-caïne	local anaesthetics of the procaine type
-cillinum	-cillin	-cilline	penicillins: derivatives of carboxy-6-amino-penicillanic acid
-cort-	-cort-	-cort-	steroids, glucocorticoids and mineralo-corticoids, other than prednisolone derivatives
-crinum	-crine	-crine	acridine derivatives, antimicrobial
-curinum	-curine	-curine	curare-like-drugs
-cyclinum	-cycline	-cycline	antibiotics, tetracycline derivatives
-dionum	-dione	-dione	antiepileptics derived from oxazolidinedione
-estr-	-estr-	-estr-	estrogenic drugs
-gest-	-gest-	-gest-	steroids, progestative
gly-	gly-	gly-	antidiabetics, oral
io-	io-	io-	iodine contrast
iod	iod	iod	iodine-containing compounds not used as contrast media
or -io-	or -io-	or -io-	
-mer-	-mer-	-mer-	mercury-containing drugs, antimicrobial or diuretic
-mycinum	-mycin	-mycine	antibiotics, produced by *Streptomyces* strains
nifur-	nifur-	nifur-	5-nitrofuran derivatives
quinum	-quine	-quine	quinoline derivatives
stigminum	-stigmine	-stigmine	anticholinesterases
	sulfa-	sulfa-	sulfonamides, used as antimicrobials
-tizidum	-tizide	-tizide	diuretics which are thiazide derivatives
-toinum	-toin	-toïne	antiepileptics which are hydantoin-derivatives
-verinum	-verine	-vérine	spasmolytics with a papaverine-like action
-olum	-ol	-ol	alcohols and phenols (-OH group)
-alum	-al	-al	aldehydes
-inum	-ine	-ine	alkaloids and organic bases
-onum	-one	-one	ketones and other substances containing the CO group
-onium	-onium	-onium	quaternary amines
-anum	-ane	-ane	saturated hydrocarbons
-enum	-ene	-ène	unsaturated hydrocarbons

CORRIGENDA

INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS

Vol. 16, No. 10, p. 391 [1]

delete	
paramethasoni acetas paramethazone acetate	6α-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 21-acetate
insert	
paramethasonum paramethasone	6α-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione

Vol. 17, No. 10, p. 392

delete	
cloramfenicoli pantotenas cloramfenicol pantotenate	chloramphenicol complex with calcium pantothenate
insert	
cloramfenicoli pantotenas compositum cloramfenicol pantotenate complex	chloramphenicol complex with calcium pantothenate

CUMULATIVE LIST OF INTERNATIONAL NON-PROPRIETARY NAMES FOR PHARMACEUTICAL PREPARATIONS [2]

p. 46

delete	*insert*
thioridazinum * (8) thioridazine	thioridazinum (8) thioridazine

[1] This correction supersedes that given in *WHO Chronicle*, 1963, 17, 79.

[2] World Health Organization (1962) *Cumulative list of proposed international non-proprietary names for pharmaceutical preparations*, Geneva.